Last reviewed · How we verify
Aloprim (ALLOPURINOL)
Aloprim works by inhibiting the enzyme xanthine oxidase, which is responsible for producing uric acid in the body.
Aloprim (Allopurinol) is a small molecule xanthine oxidase inhibitor developed by Prometheus Labs and currently owned by Casper Pharma Llc. It targets xanthine dehydrogenase/oxidase to treat various conditions, including articular gout, calcium renal calculus, and chemotherapy-induced hyperuricemia. FDA-approved in 1966, Aloprim is now off-patent with 22 generic manufacturers. Key safety considerations include its short half-life of 0.8 hours and moderate bioavailability of 53%. As an off-patent medication, it is widely available in the market.
At a glance
| Generic name | ALLOPURINOL |
|---|---|
| Sponsor | Casper Pharma Llc |
| Drug class | Xanthine Oxidase Inhibitor [EPC] |
| Target | Xanthine dehydrogenase/oxidase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 1966 |
Mechanism of action
Allopurinol is structural analogue of the natural purine base, hypoxanthine. Allopurinol and its oxypurinol metabolite inhibitor xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine and of xanthine to uric acid, the end product of purine metabolism in humans. Allopurinol does not disrupt the biosynthesis of purines.The action of oral allopurinol differs from that of uricosuric agents, which lower the serum uric acid level by increasing urinary excretion of uric acid. Allopurinol reduces both the serum and urinary uric acid levels by inhibiting the formation of uric acid. The use of allopurinol to block the formation of urates avoids the hazard of increased renal excretion of uric acid posed by uricosuric drugs.
Approved indications
- Articular gout
- Calcium renal calculus
- Chemotherapy-Induced Hyperuricemia
- Gout
- Hyperuricemia
- Recurrent Calcium Renal Calculi
- Uric Acid Nephropathy Gout
- Uric acid renal calculus
Boxed warnings
- BOXED WARNING
Common side effects
- Drug reaction with eosinophilia and systemic symptoms
- Acute kidney injury
- Anaemia
- Hyperkalaemia
- Renal failure
- Toxic epidermal necrolysis
- Gout
- Febrile neutropenia
- Pemphigus
- Maternal exposure during pregnancy
- Stevens-Johnson syndrome
- Systemic lupus erythematosus
Drug interactions
- amoxicillin
- azathioprine
- didanosine
- mercaptopurine
- warfarin
Key clinical trials
- A Study of Dotinurad Versus Allopurinol in Tophaceous Gout (PHASE3)
- A Study of Dotinurad Versus Allopurinol in Participants With Gout (PHASE3)
- Evaluation of a Treatment With Allopurinol in Adenylosuccinate Lyase Deficiency (PHASE2)
- Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia (PHASE3)
- Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines - (DREAM) Probenecid vs Allopurinol
- Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT) (PHASE2)
- Time Required to Dissolve Urate Deposits
- Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aloprim CI brief — competitive landscape report
- Aloprim updates RSS · CI watch RSS
- Casper Pharma Llc portfolio CI